Garrido Valéria, Barros Caroline, Melchiades Vanessa A, Fonseca Rainomar Raimundo, Pinheiro Sergio, Ocampo Patrícia, Teixeira Valéria L, Cavalcanti Diana N, Giongo Viveca, Ratcliffe Norman A, Teixeira Gerlinde, Paixão Izabel Christina N P
Department of Cellular and Molecular Biology, Laboratory of Molecular Virology Molecular - Biology Institute, Federal Fluminense University (UFF), Science and Biotechnology Postgraduate Program, Campos do Valonguinho, sn, Niterói, RJ, 24020-150, Brazil.
Department of Cellular and Molecular Biology, Laboratory of Molecular Virology Molecular - Biology Institute, Federal Fluminense University (UFF), Science and Biotechnology Postgraduate Program, Campos do Valonguinho, sn, Niterói, RJ, 24020-150, Brazil.
Regul Toxicol Pharmacol. 2017 Jun;86:193-198. doi: 10.1016/j.yrtph.2017.03.007. Epub 2017 Mar 8.
This study examined in rats the subchronic toxicity and anti- HSV-1activity after oral administration of dolabelladienetriol (D1), a diterpene isolated from the seaweed Dictyota pfaffii. In subchronic toxicity (SCT) tests, female rats received D1 by gavage 15 mg/kg/day (n = 5) for 50 days, and general behavior, death, hematological, biochemical and histological changes in the liver, kidney, stomach, and duodenum were determined. For the anti-HSV-1 activity, female mice were infected and treated orally with a dose of 20 mg/kg (n = 5) twice a day with D1 and any lesions in the skin were then recorded for 18 days. Dolabelladienetriol in SCT did not significantly change behavior, body weight, hematological or biochemical profiles. The liver and kidneys, however, showed some alterations in rats treated with D1, similar to those in rats treated with ACV, while the other tissues had no significant changes. The anti-HSV-1 activity of D1 had a similar efficacy to the ACV drug control in mice. Our results showed that D1 has potential commercial development as a new HSV-1drug.
本研究在大鼠中检测了从海藻Pfaffii网地藻中分离出的二萜类化合物多拉贝拉二烯三醇(D1)口服给药后的亚慢性毒性和抗单纯疱疹病毒1型(HSV-1)活性。在亚慢性毒性(SCT)试验中,雌性大鼠通过灌胃给予D1,剂量为15毫克/千克/天(n = 5),持续50天,测定其一般行为、死亡情况、血液学指标、生化指标以及肝脏、肾脏、胃和十二指肠的组织学变化。对于抗HSV-1活性,雌性小鼠感染后,每天两次口服给予20毫克/千克剂量的D1(n = 5),然后记录18天皮肤的任何病变情况。在SCT中,多拉贝拉二烯三醇并未显著改变行为、体重、血液学或生化指标。然而,在用D1处理的大鼠中,肝脏和肾脏出现了一些变化,类似于用阿昔洛韦(ACV)处理的大鼠,而其他组织没有显著变化。D1的抗HSV-1活性在小鼠中与ACV药物对照具有相似的疗效。我们的结果表明,D1作为一种新型HSV-1药物具有潜在的商业开发价值。